3SBio's Sunshine Guojian Files First Global IND for IL-23×TL1A BsAb
Chinagene's Ophthalmic Gene Therapy Enters Priority Review in China
BeiGene Raises Full-Year Guidance as H1 Revenue Hits RMB 22.22bn
Takeda Places First OX2R Agonist for Type 1 Narcolepsy in US Market
Lilly H1 2026: Tirzepatide Reaches USD 27.7bn, Revenue Up 49%